OncoMatch/Clinical Trials/NCT07188246
Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer
Is NCT07188246 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Pembrolizumab (KEYTRUDA®) for breast cancer.
Treatment: Pembrolizumab (KEYTRUDA®) — This study will evaluate the immune-priming effects of stereotactic body radiation therapy (SBRT) regimen coupled with two injections of pembrolizumab in high-risk primary breast carcinoma prior to neoadjuvant chemotherapy. Preliminary results from the investigators' local TRIO Trial suggest that SBRT prior to neoadjuvant chemotherapy (NAC) may result in improved response rates due to the combined effect of radiation therapy (RT) and chemotherapy. The investigators aim to augment this effect with the addition of pembrolizumab, a monoclonal antibody that binds to and blocks programmed cell death protein 1 (PD-1).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Breast Carcinoma
Triple-Negative Breast Cancer
Disease stage
Required: Stage IIB, III (AJCC 8th edition)
Excluded: Stage INFLAMMATORY BREAST CANCER
Invasive mammary carcinoma of stages IIB - III (excluding inflammatory breast cancer). Stage IIA is eligible for triple negative and HER2+ breast cancers.
Prior therapy
Cannot have received: any treatment for current breast cancer
Prior treatment for current breast cancer.
Cannot have received: radiation therapy to the same breast
Previous radiation therapy to the same breast.
Cannot have received: stem cell transplantation
No prior stem cell transplantation.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07188246 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage IIB or III is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify